Helios ties paid option grants to ARDS approval and a ¥1.5bn sales hurdle
The 29th option series can be exercised only if Helios wins domestic approval for HLCM051 in ARDS and records at least ¥1.5bn of revenue in any year through 2032. Full exercise would equal 9.0% of shares outstanding, while the same-day 28th, 29th and 30th series together reach 14.0% dilution.